{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:51:40Z","timestamp":1794495100973,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Richard-Winter-Stiftung","award":["PhD scholarship"],"award-info":[{"award-number":["PhD scholarship"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00259-018-4220-z","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T22:12:06Z","timestamp":1546467126000},"page":"1081-1091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Development and dosimetry of 203Pb\/212Pb-labelled PSMA ligands: bringing \u201cthe lead\u201d into PSMA-targeted alpha therapy?"],"prefix":"10.1007","volume":"46","author":[{"given":"Jos\u00e9 Carlos","family":"dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bauder-W\u00fcst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencke","family":"Lehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Leotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kopka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Mier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-8260","authenticated-orcid":false,"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"4220_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/cbr.2013.1549","volume":"29","author":"G Rubini","year":"2014","unstructured":"Rubini G, Nicoletti A, Rubini D, Asabella AN. Radiometabolic treatment of bone-metastasizing cancer: from 186Rhenium to 223Radium. Cancer Biother Radiopharm. 2014;29:1\u201311. \n                    https:\/\/doi.org\/10.1089\/cbr.2013.1549\n                    \n                  .","journal-title":"Cancer Biother Radiopharm"},{"key":"4220_CR2","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624\u201331. \n                    https:\/\/doi.org\/10.2967\/jnumed.117.191395\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"4220_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795\u2013802. \n                    https:\/\/doi.org\/10.2967\/jnumed.117.203539\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"4220_CR4","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","volume":"41","author":"C Kratochwil","year":"2014","unstructured":"Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106\u201319. \n                    https:\/\/doi.org\/10.1007\/s00259-014-2857-9\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4220_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0969-8051(99)00086-4","volume":"27","author":"LL Chappell","year":"2000","unstructured":"Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 2000;27:93\u2013100. \n                    https:\/\/doi.org\/10.1016\/S0969-8051(99)00086-4\n                    \n                  .","journal-title":"Nucl Med Biol"},{"key":"4220_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1039\/C39890000145","volume":"0","author":"K Kumar","year":"1989","unstructured":"Kumar K, Magerst\u00e4dt M, Gansow OA. Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta. J Chem Soc Chem Commun. 1989;0:145\u20136. \n                    https:\/\/doi.org\/10.1039\/C39890000145\n                    \n                  .","journal-title":"J Chem Soc Chem Commun"},{"key":"4220_CR7","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1021\/ja00130a008","volume":"117","author":"H Maumela","year":"1995","unstructured":"Maumela H, Hancock RD, Carlton L, Reibenspies JH, Wainwright KP. The amide oxygen as a donor group. Metal ion complexing properties of tetra-N-acetamide substituted cyclen: a crystallographic, NMR, molecular mechanics, and thermodynamic study. J Am Chem Soc. 1995;117:6698\u2013707. \n                    https:\/\/doi.org\/10.1021\/ja00130a008\n                    \n                  .","journal-title":"J Am Chem Soc"},{"key":"4220_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Benesova","year":"2015","unstructured":"Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914\u201320. \n                    https:\/\/doi.org\/10.2967\/jnumed.114.147413\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"4220_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.7150\/thno.13448","volume":"6","author":"T W\u00fcstemann","year":"2016","unstructured":"W\u00fcstemann T, Bauder-W\u00fcst U, Sch\u00e4fer M, Eder M, Benesova M, Leotta K, et al. Design of internalizing PSMA-specific Glu-ureido-based radiotherapeuticals. Theranostics. 2016;6:1085\u201395. \n                    https:\/\/doi.org\/10.7150\/thno.13448\n                    \n                  .","journal-title":"Theranostics"},{"key":"4220_CR10","first-page":"1245","volume":"43","author":"S Shen","year":"2002","unstructured":"Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non\u2013marrow-targeting 90Y-antibody therapy. J Nucl Med. 2002;43:1245\u201353.","journal-title":"J Nucl Med"},{"key":"4220_CR11","first-page":"689","volume":"34","author":"G Sgouros","year":"1993","unstructured":"Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689\u201394.","journal-title":"J Nucl Med"},{"key":"4220_CR12","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"4220_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311\u201328.","journal-title":"J Nucl Med"},{"key":"4220_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2307\/3579579","volume":"148","author":"LE Feinendegen","year":"1997","unstructured":"Feinendegen LE, McClure JJ. Alpha-emitters for medical therapy: Workshop of the United States Department of Energy: Denver, Colorado, May 30\u201331, 1996. Radiat Res. 1997;148:195\u2013201.","journal-title":"Radiat Res"},{"key":"4220_CR15","first-page":"149","volume":"41","author":"MG Stabin","year":"2000","unstructured":"Stabin MG, Konijnenberg M. Re-evaluation of absorbed fractions for photons and electrons in small spheres. J Nucl Med. 2000;41:149\u201360.","journal-title":"J Nucl Med"},{"key":"4220_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00259-017-3817-y","volume":"45","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45:31\u20137. \n                    https:\/\/doi.org\/10.1007\/s00259-017-3817-y\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4220_CR17","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1021\/jm801055h","volume":"51","author":"Y Chen","year":"2008","unstructured":"Chen Y, Foss CA, Byun Y, Pullambhatla M, Fox JJ, Castanares M, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008;51:7933\u201343.","journal-title":"J Med Chem"},{"issue":"24","key":"4220_CR18","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1021\/jm800765e","volume":"51","author":"C Barinka","year":"2008","unstructured":"Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 2008;51(24):7737\u201343.","journal-title":"J Med Chem"},{"key":"4220_CR19","doi-asserted-by":"publisher","first-page":"12711","DOI":"10.1021\/ja104591m","volume":"132","author":"AX Zhang","year":"2010","unstructured":"Zhang AX, Murelli RP, Barinka C, Michel J, Cocleaza A, Jorgensen WL, et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 2010;132:12711\u20136.","journal-title":"J Am Chem Soc"},{"key":"4220_CR20","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","volume":"59","author":"M Benesova","year":"2016","unstructured":"Benesova M, Bauder-Wust U, Schafer M, Klika KD, Mier W, Haberkorn U, et al. Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem. 2016;59:1761\u201375.","journal-title":"J Med Chem"},{"key":"4220_CR21","doi-asserted-by":"crossref","unstructured":"Kopka K, Bene\u0161ov\u00e1 M, Ba\u0159inka C, Haberkorn U, Babich J. Glu-ureido-based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers. J Nucl Med. 2017;58(Suppl 2):17S\u201326S.","DOI":"10.2967\/jnumed.116.186775"},{"key":"4220_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/2191-219X-2-23","volume":"2","author":"M Sch\u00e4fer","year":"2012","unstructured":"Sch\u00e4fer M, Bauder-W\u00fcst U, Leotta K, Zoller F, Mier W, Haberkorn U, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2:23.","journal-title":"EJNMMI Res"},{"issue":"1","key":"4220_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sj\u00f6green-Gleisner K, et al. MIRD pamphlet no. 26: joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151\u201362. \n                    https:\/\/doi.org\/10.2967\/jnumed.115.159012\n                    \n                  .","journal-title":"J Nucl Med"},{"issue":"1","key":"4220_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1524\/ract.1993.60.1.1","volume":"60","author":"S Mirzadeh","year":"1993","unstructured":"Mirzadeh S, Kumar K, Gansow OA. The chemical fate of 212Bi-DOTA formed by \u03b2\u2212 decay of 212Pb(DOTA)2\u2212. Radiochim Acta. 1993;60(1):1\u201310. \n                    https:\/\/doi.org\/10.1524\/ract.1993.60.1.1\n                    \n                  .","journal-title":"Radiochim Acta"},{"key":"4220_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/0360-3016(95)02119-1","volume":"34","author":"G Ruble","year":"1996","unstructured":"Ruble G, Wu C, Squire RA, Gansow OA, Strand M. The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int J Radiat Oncol Biol Phys. 1996;34:609\u201316.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4220_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069613","volume":"8","author":"V Boudousq","year":"2013","unstructured":"Boudousq V, Bobyk L, Busson M, Garambois V, Jarlier M, Charalambatou P, et al. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One. 2013;8:e69613. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0069613\n                    \n                  .","journal-title":"PLoS One"},{"key":"4220_CR27","first-page":"26","volume":"133","author":"JH McKillp","year":"1980","unstructured":"McKillp JH. Thallium 201 scintigraphiy. West J Med. 1980;133:26\u201343.","journal-title":"West J Med"},{"key":"4220_CR28","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","volume":"56","author":"J Schwartz","year":"2011","unstructured":"Schwartz J, Jaggi JS, O'Donoghue JA, Ruan S, McDevitt M, Larson SM, et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56:721\u201333.","journal-title":"Phys Med Biol"},{"issue":"2","key":"4220_CR29","first-page":"252","volume":"44","author":"G Henriksen","year":"2003","unstructured":"Henriksen G, Fisher DR, Roeske JC, Bruland \u00d8S, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252\u20139.","journal-title":"J Nucl Med"},{"key":"4220_CR30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/ph8030416","volume":"8","author":"DE Milenic","year":"2015","unstructured":"Milenic DE, Molinolo AA, Solivella MS, Banaga E, Torgue J, Besnainou S, et al. Toxicological studies of 212Pb intravenously or intraperitoneally injected into mice for a phase 1 trial. Pharmaceuticals (Basel). 2015;8:416\u201334.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4220_CR31","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00259-017-3657-9","volume":"44","author":"M Sathekge","year":"2017","unstructured":"Sathekge M, Knoesen O, Meckel M, Modiselle M, Vorster M, Marx S. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1099\u2013100. \n                    https:\/\/doi.org\/10.1007\/s00259-017-3657-9\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"4220_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/cbr.2013.1531","volume":"29","author":"RF Meredith","year":"2014","unstructured":"Meredith RF, Torgue J, Azure MT, Garambois V, Jarlier M, Charalambatou P, et al. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 2014;29(1):12\u20137.","journal-title":"Cancer Biother Radiopharm"},{"issue":"10","key":"4220_CR33","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.2967\/jnumed.114.143842","volume":"55","author":"R Meredith","year":"2014","unstructured":"Meredith R, Torgue J, Shen S, Fisher DR, Banaga E, Bunch P, et al. Dose escalation and dosimetry of first-in-human \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med. 2014;55(10):1636\u201342.","journal-title":"J Nucl Med"},{"key":"4220_CR34","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2967\/jnumed.107.048553","volume":"49","author":"Y Miao","year":"2008","unstructured":"Miao Y, Figueroa SD, Fisher DR, Moore HA, Testa RF, Hoffman TJ, et al. 203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med. 2008;49:823\u20139.","journal-title":"J Nucl Med"},{"key":"4220_CR35","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1158\/1078-0432.CCR-05-0619","volume":"11","author":"Y Miao","year":"2005","unstructured":"Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, et al. Melanoma therapy via peptide-targeted \u03b1-radiation. Clin Cancer Res. 2005;11:5616\u201321.","journal-title":"Clin Cancer Res"},{"key":"4220_CR36","doi-asserted-by":"publisher","unstructured":"Tworowska I, Stallons T, Saidi A, Wagh N, Rojas-Quijano F, Jurek P, et al. Pb203-AR-RMX conjugates for image-guided TAT of neuroendocrine tumors (NETs). Cancer Res. 2017;77(13 Suppl) LB-259. \n                    https:\/\/doi.org\/10.1158\/1538-7445.AM2017-LB-259\n                    \n                  .","DOI":"10.1158\/1538-7445.AM2017-LB-259"},{"key":"4220_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.04.005","volume":"51","author":"S Westr\u00f8m","year":"2017","unstructured":"Westr\u00f8m S, Generalov R, B\u00f8nsdorff TB, Larsen RH. Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution. Nucl Med Biol. 2017;51:1\u20139.","journal-title":"Nucl Med Biol"},{"key":"4220_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.apradiso.2017.05.006","volume":"127","author":"M Li","year":"2017","unstructured":"Li M, Zhang X, Quinn TP, Lee D, Liu D, Kunkel F, et al. Automated cassette-based production of high specific activity [203\/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Appl Radiat Isot. 2017;127:52\u201360.","journal-title":"Appl Radiat Isot"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-018-4220-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T19:32:51Z","timestamp":1577993571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-018-4220-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4220"],"URL":"https:\/\/doi.org\/10.1007\/s00259-018-4220-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"8 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K.K, U.H and C.K.: patent for PSMA-617. J.C.dos S., M.S., U.B., U.H., W.M., C.K.: patent application for novel intellectual property presented in this article. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed on animals were carried out in accordance with the laws on animal welfare of the Federal Republic of Germany and were approved by the local research committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement on the welfare of animals"}},{"value":"We report observations from clinical practice. Our institutional Ethics Committee certified (permit S-321\/2012) that this retrospective evaluation complied with our national regulations and with the principles of the updated version of the Declaration of Helsinki. For this type of study clinical trial registration is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"All patients were informed about the in-house production of the novel radiopharmaceutical according to the German Pharmaceuticals Act \u00a713(2b), and gave written informed consent to their participation in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}